Orthovita to Present at UBS Global Life Sciences Conference.MALVERN, Pa. -- Orthovita, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :VITA), a developer of orthopedic biomaterials, announced today that it will participate as a presenting company at the UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference. Antony Koblish, president and chief executive officer of Orthovita, is scheduled to present on Monday, September 25th, at 1:30p.m. Eastern Time, at the Grand Hyatt Hotel, Park Avenue at Grand Central, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY. A live webcast of this presentation will be available at www.ibb.ubs.com by clicking on the "Conferences" link. About the Company Orthovita is a biosurgery company with proprietary biomaterial technologies for the development and commercialization of synthetic, biologically active, tissue engineering products for orthopedic and neurosurgical applications. Our products are used in the regeneration of bone and soft tissue. Our near-term commercial business is based on our VITOSS(R) Bone Graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft autograft: see transplantation, medical. or cadaver-derived bone material to meet a broad range of orthopedic clinical needs in the spine, trauma, joint reconstruction, revision surgery and extremities markets, and VITAGEL(TM) Surgical Hemostat hemostat /he·mo·stat/ (he´mo-stat) 1. a small surgical clamp for constricting blood vessels. 2. an antihemorrhagic agent. he·mo·stat n. 1. , which is an adherent adherent /ad·her·ent/ (-ent) sticking or holding fast, or having such qualities. matrix and an impermeable impermeable /im·per·me·a·ble/ (-per´me-ah-b'l) not permitting passage, as of fluid. im·per·me·a·ble adj. Impossible to permeate; not permitting passage. barrier to blood flow. Our longer-term U.S. clinical development program is focused on our CORTOSS(R) Synthetic Cortical Bone technology platform, which is designed for injections in osteoporotic spines to treat vertebral compression fractures. Orthovita works jointly with Kensey Nash Corporation and Angiotech Pharmaceuticals, Inc. to develop and market novel synthetic-based biomaterial products, and continues to pursue similar relationships with other companies in biomaterials. Cautionary Note Regarding Forward-Looking Statements This press release may contain forward-looking statements regarding Orthovita's current expectations of future events that involve risks and uncertainties as listed from time to time in reports we file with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K and Form 10-Q under the caption "Certain Risks Related to Our Business". Further information about these and other relevant risks and uncertainties may be found in Orthovita's filings with the SEC, all of which are available from the SEC as well as from Orthovita upon request. Orthovita undertakes no obligation to publicly update any forward-looking statements. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion